Safety and efficacy of Qurse-e-istisqua in chronic hepatitis C Infection an exploratory study (Record no. 23699)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02229 a2200217 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20251203145657.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 251203b |||||||| |||| 00| 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | AIKTC-KRRC |
| Transcribing agency | AIKTC-KRRC |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Author | Rehan, Harmeet Singh |
| 9 (RLIN) | 27646 |
| 245 ## - TITLE STATEMENT | |
| Title | Safety and efficacy of Qurse-e-istisqua in chronic hepatitis C Infection an exploratory study |
| 250 ## - EDITION STATEMENT | |
| Volume, Issue number | Vol.47(1), Jan-Feb |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | Mumbai |
| Name of publisher, distributor, etc. | Wolter Kluwer |
| Year | 2015 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Pagination | 72-79p. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Qurse-e-istisqua (Q-e-I), an Unani medicine commonly prescribed to treat liver disorders.<br/>Objectives: <br/>To study efficacy and safety of Q-e-I in hepatitis C virus (HCV) infection.<br/>Methods: <br/><br/>In this randomized double-blind exploratory study, 60 naive patients of HCV infection were assigned to receive either interferonα2a (IFNα2a) (3 mIU, subcutaneous, thrice weekly), ribavirin (RBV) (1000 mg, orally, twice daily in divided doses) and placebo (n = 30) or IFNα2a, RBV and Q-e-I (5 g, orally, thrice daily in divided doses) (n = 30). HCV RNA levels, serum hyaluronic acid (SHA), ultrasound image scoring for fibrosis, liver and renal function test, prothrombin time, were done at the baseline and thereafter periodically.<br/>Results: <br/><br/>Early virologic response (EVR), end of treatment response (ETR) and sustained virologic response (SVR) were 90%, 96.6% and 90% in the control group and 86.6%, 90.0% and 83.3% in the treatment group. SHA level was lower in the treatment group at the end of the treatment as compared to the control group. Mean end of follow-up ultrasound image scoring for fibrosis in the control and the treatment group was 1.37 ± 0.07 and 1.22 ± 0.06 respectively. Aspartate aminotransferase (AST) levels were significantly lower in the treatment group than the control group at 1-month. Commonly observed adverse drug reactions included fever, hair fall, fatigue, anemia, and diarrhea. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | PHARMACOLOGY |
| 9 (RLIN) | 4774 |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Co-Author | Chopra, Deepti |
| 9 (RLIN) | 27647 |
| 773 0# - HOST ITEM ENTRY | |
| International Standard Serial Number | 0253-7613 |
| Title | Indian Journal of Pharmacology |
| Place, publisher, and date of publication | Andheri - Mumbai Wolters Kluwer India Private Limited |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| URL | https://journals.lww.com/iphr/fulltext/2015/47010/safety_and_efficacy_of_qurse_e_istisqua_in_chronic.14.aspx |
| Link text | Click here |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Articles Abstract Database |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Home library | Current library | Shelving location | Date acquired | Total Checkouts | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | School of Pharmacy | School of Pharmacy | Archieval Section | 03/12/2025 | 2025-1734 | 03/12/2025 | 03/12/2025 | Articles Abstract Database |